ArticlePreventive medicine reports2026
Long-term impact of the COVID-19 pandemic on childhood vaccination coverage in Quebec, Canada: A cohort study from the Canadian immunization research network.
Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The COVID-19 pandemic disrupted routine childhood vaccination globally, increasing the risk of resurgences of vaccine-preventable diseases. This study assessed the long-term impact of the pandemic on vaccination coverage and timeliness for routine childhood immunizations for children born in 2017-2023. Methods: We conducted a retrospective cohort study in Quebec, Canada, using data from the Quebec Immunization Registry. We compared age-appropriate vaccination coverage by 3, 5, 13 and 19 months of age and the cumulative days undervaccinated during the first 24 months of life, from 2019 to 2023. Results: There was no decrease in vaccination coverage by 3 and 5 months of age in 2023 compared to 2019 for DTaP, Hepatitis B, rotavirus and pneumococcal conjugate vaccines. We observed a 0.8 percentage point decline (95% confidence intervals (CI):-1.2,-0.4) for ≥1 dose of the measles vaccine by 13 months of age, and a 1.0 percentage point decline (95%CI:-1.5,-0.06) for ≥2 doses by 19 months of age in 2023 compared to 2019. Overall, the mean number of days undervaccinated decreased across birth cohorts from 158.8 in 2019 to 133.8 in 2023. Conclusion: Delays in the administration of the measles vaccine remain concerning. Sustained efforts are needed to maintain high vaccination coverage and prevent outbreaks of vaccine-preventable diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.